Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Zhong Ji Longevity Science Group Limited ( (HK:0767) ) is now available.
Zhong Ji Longevity Science Group Limited, a Hong Kong-listed longevity and life-sciences company focusing on cellular technologies and related healthcare applications, is pursuing an expansion of its interests through the proposed acquisition of 25% of Asian Integrated Cell Laboratory Limited, to be funded via the issue of convertible notes under a specific mandate. The company has announced a further delay in sending a shareholder circular detailing this major and connected transaction, pushing the expected dispatch date from 16 January 2026 to on or before 9 February 2026, as additional time is needed to prepare and finalise required information; the postponement may slightly extend the timetable for shareholder approval and completion but does not alter the transaction’s proposed structure or strategic intent.
The most recent analyst rating on (HK:0767) stock is a Sell with a HK$0.50 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.
More about Zhong Ji Longevity Science Group Limited
Zhong Ji Longevity Science Group Limited is a Bermuda-incorporated, Hong Kong-listed company (stock code: 767). The group operates in the longevity and life-sciences sector, with a strategic focus on cellular technologies and related healthcare applications, reflected in its plan to acquire a stake in Asian Integrated Cell Laboratory Limited.
Average Trading Volume: 509,549
Technical Sentiment Signal: Hold
Current Market Cap: HK$337.4M
For a thorough assessment of 0767 stock, go to TipRanks’ Stock Analysis page.